BiotechTube

Ranexa + Placebo

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cardiomyopathy

Conditions

Cardiomyopathy, Chest Pain, Dyspnea

Trial Timeline

Apr 1, 2011 → Apr 1, 2014

NCT ID
NCT01345188

About Ranexa + Placebo

Ranexa + Placebo is a approved stage product being developed by Gilead Sciences for Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01345188. Target conditions include Cardiomyopathy, Chest Pain, Dyspnea.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01345188ApprovedCompleted

Competing Products

20 competing products in Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Tideglusib + PlaceboAMO PharmaPhase 2
44
MavacamtenLianBioPhase 1
25
Mavacamten + PlaceboLianBioPhase 3
69
CT-G20 + PlaceboCelltrionPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
85
AZD0233 + AZD0233 PlaceboAstraZenecaPhase 1
33
AZD4063AstraZenecaPhase 1
33
EplontersenAstraZenecaPhase 3
77
Eplontersen + PlaceboAstraZenecaPhase 3
77
candesartanAstraZenecaPhase 2
52
LCZ696 + PlaceboNovartisPhase 2
52
Darbepoetin alfaAmgenPre-clinical
22
Eleclazine + PlaceboGilead SciencesPhase 2/3
64
RanolazineGilead SciencesApproved
84
RanolazineGilead SciencesPre-clinical
22
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3
76
NNC6019-0001Novo NordiskPhase 2
51
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 2
51
CoramitugNovo NordiskPhase 1
32

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved
84
Truvada + Atazanavir + RitonavirApproved
84
Truvada + efavirenzApproved
84
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved
84
TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved
84